Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Arcutis Biotherapeutics Inc maintains a gross margin of 90.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.20%, while the net margin is 13.43%. These profitability ratios, combined with a Return on Equity (ROE) of -9.30%, provide a clear picture of how effectively ARQT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ARQT competes directly with industry leaders such as SYRE and KNSA. With a market capitalization of $3.07B, it holds a significant position in the sector. When comparing efficiency, ARQT's gross margin of 90.97% stands against SYRE's N/A and KNSA's 88.80%. Such benchmarking helps identify whether Arcutis Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
